BiotechTube

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Japanese Encephalitis

Conditions

Japanese Encephalitis

Trial Timeline

Jun 1, 2015 → Jun 1, 2016

NCT ID
NCT02492165

About Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02492165. Target conditions include Japanese Encephalitis.

What happened to similar drugs?

3 of 20 similar drugs in Japanese Encephalitis were approved

Approved (3) Terminated (0) Active (17)
✅IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine + IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccineSanofiApproved
✅IXIARO®- Japanese Encephalitis vaccineValneva SEApproved
✅IXIARO®Valneva SEApproved
🔄MEDI3250 + PlaceboAstraZenecaPhase 3
🔄MEDI3250AstraZenecaPhase 3
🔄ChimeriVax™-JE + JE-VAX®SanofiPhase 3
🔄Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)SanofiPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02492165Phase 3Completed

Competing Products

20 competing products in Japanese Encephalitis

See all competitors
ProductCompanyStageHype Score
ASP3325 + PlaceboAstellas PharmaPhase 1
29
E6130 + PlaceboEisaiPhase 1
29
E2022 + E2022 + E2022 + E2022 + E2022EisaiPhase 1
29
AZD3293 + PlaceboAstraZenecaPhase 1
29
MEDI3250 + PlaceboAstraZenecaPhase 3
40
MEDI3250AstraZenecaPhase 3
40
Fostamatinib 100mg + Fostamatinib 200mgAstraZenecaPhase 1
29
NXL104 + CAZ104 + PlaceboPfizerPhase 1
29
CAIV-T + PlaceboPfizerPhase 1
29
ChimeriVax™-JE + JE-VAX®SanofiPhase 3
40
ChimeriVax™-JE + Japanese Encephalitis Inactivated Mouse Brain VaccineSanofiPhase 2
35
Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + ChimeriVax™ diluent (Placebo)SanofiPhase 2
35
ChimeriVax™-JE vaccine + JE-VAX® vaccineSanofiPhase 2
35
Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)SanofiPhase 3
40
IMOJEVSanofiPhase 3
40
a live attenuated chimeric JE vaccineSanofiPre-clinical
26
Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virusSanofiPhase 3
40
IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine + IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccineSanofiApproved
43
JE-CV Vaccine + Varicella VaccineSanofiPhase 3
40
Live attenuated Japanese encephalitis virus; Yellow fever virus + Yellow fever virus; Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus; Yellow fever virus + Live attenuated Japanese encephalitis virus; Yellow fever virusSanofiPhase 2
35